Siga Technologies Inc (SIGA) 1.6700 $SIGA
SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
BusinessWire - Mon Apr 25, 3:30PM CDT
SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it has begun enrolling the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX (tecovirimat), for the treatment of orthopoxvirus. This Phase III study, which is wholly funded the by the Biomedical Advanced Research and Development Authority (BARDA) will be conducted at eleven approved investigative sites with a total of approximately 360 subjects.
SIGA Technologies Receives NASDAQ Delisting Notification
BusinessWire - Wed Mar 18, 3:52PM CDT
SIGA Technologies, Inc. ("SIGA"
, a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it received a letter today from the Hearings Advisor for The NASDAQ Stock Market LLC ("NASDAQ" , indicating that the NASDAQ Hearings Panel has determined to delist the shares of the Company from the NASDAQ Stock Market and accordingly, suspend trading in the Company's shares effective at the open of business on March 20, 2015. SIGA expects its shares to continue to trade on the OTC Markets under the "SIGAQ" symbol.
PIP: 2.49 (unch)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 27.11 (+1.24), JNJ: 122.85 (+0.34), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57), NNVC: 1.67 (-0.03), GSK: 43.38 (+0.04)
SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery
BusinessWire - Fri Jan 16, 3:10PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that it has filed a notice of appeal from the judgment of the Delaware Court of Chancery awarding PharmAthene, Inc. expectation damages.
PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery
PR Newswire - Thu Jan 15, 3:08PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the Company's litigation against SIGA Technologies, Inc. The Court's judgment against SIGA totaled $194,649,041.74, including $113,116,985.00 in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, and $81,532,056.74 in pre-judgment interest and attorneys' and expert witness fees. In addition, SIGA will be required to pay post-judgment interest of $30,663.89 per day, beginning today.
PIP: 2.49 (unch)
Delaware Court Decision Regarding SIGA Technologies, Inc.
BusinessWire - Wed Jan 07, 4:29PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that on January 7, 2015, the Delaware Court of Chancery, acting on remand from the Delaware Supreme Court, issued a letter opinion in the litigation begun by PharmAthene, Inc. in 2006.
Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014
PRWeb - Fri Nov 28, 7:30PM CST
The report "Poxvirus Infections Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.reportsnreports.com/reports/318830...-2014.html .
PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment
PR Newswire - Wed Oct 08, 11:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially lifted the stay of PharmAthene's litigation against SIGA Technologies, Inc., in the Delaware Court of Chancery. The order allows the Chancery Court to issue a final judgment and the parties to pursue appeals thereof. Enforcement of any judgment, once entered will remain subject to the Bankruptcy Court stay.
PIP: 2.49 (unch)
SIGA Announces Enrollment of First Patients in the Final Cohort of Phase III Study of Tecovirimat
BusinessWire - Mon Apr 25, 3:30PM CDT
SIGA Technologies, Inc. (SIGA) (OTCMKTS:SIGA), a company specializing in the development of pharmaceutical agents to combat bio-warfare pathogens, announced today that it has begun enrolling the second and final cohort of healthy subjects for the Phase III clinical study for its lead drug candidate, TPOXX (tecovirimat), for the treatment of orthopoxvirus. This Phase III study, which is wholly funded the by the Biomedical Advanced Research and Development Authority (BARDA) will be conducted at eleven approved investigative sites with a total of approximately 360 subjects.
SIGA Technologies Receives NASDAQ Delisting Notification
BusinessWire - Wed Mar 18, 3:52PM CDT
SIGA Technologies, Inc. ("SIGA"
, a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that it received a letter today from the Hearings Advisor for The NASDAQ Stock Market LLC ("NASDAQ" , indicating that the NASDAQ Hearings Panel has determined to delist the shares of the Company from the NASDAQ Stock Market and accordingly, suspend trading in the Company's shares effective at the open of business on March 20, 2015. SIGA expects its shares to continue to trade on the OTC Markets under the "SIGAQ" symbol. PIP: 2.49 (unch)
Dengue Therapeutic Pipeline Drugs and Companies Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Fri Jan 23, 7:45PM CST
The report "Dengue - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Dengue. Dengue is a disease caused by bite of the mosquito (Aedes Mosquito) which is infected with a dengue virus. The disease can affect a person through fever, headache, muscle and joint pain. The disease if not cured on time may result into fatal occurrences like dengue hemorrhagic fever. The disease may also result in failure of the circulatory systems of the body. Dengue is found in the Asian Subcontinent. These are primarily the regions wherein the population is crowded & there is scope for the mosquitoes to quantify. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. Complete Report is Available @ http://www.rnrmarketresearch.com/dengue-pipel...eport.html .
MGNX: 27.11 (+1.24), JNJ: 122.85 (+0.34), UTHR: 111.16 (+1.58), MRK: 59.35 (+0.57), NNVC: 1.67 (-0.03), GSK: 43.38 (+0.04)
SIGA Technologies, Inc. Appeals Judgment of Delaware Court of Chancery
BusinessWire - Fri Jan 16, 3:10PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today announced that it has filed a notice of appeal from the judgment of the Delaware Court of Chancery awarding PharmAthene, Inc. expectation damages.
PharmAthene Awarded $195 Million Plus Post-Judgment Interest By Delaware Court Of Chancery
PR Newswire - Thu Jan 15, 3:08PM CST
PharmAthene, Inc. (NYSE MKT: PIP) announced today that the Delaware Court of Chancery has entered its Final Order and Judgment in the Company's litigation against SIGA Technologies, Inc. The Court's judgment against SIGA totaled $194,649,041.74, including $113,116,985.00 in lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat, and $81,532,056.74 in pre-judgment interest and attorneys' and expert witness fees. In addition, SIGA will be required to pay post-judgment interest of $30,663.89 per day, beginning today.
PIP: 2.49 (unch)
Delaware Court Decision Regarding SIGA Technologies, Inc.
BusinessWire - Wed Jan 07, 4:29PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA), a company operating under the protection of the United States Bankruptcy Court for the Southern District of New York and specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, announced that on January 7, 2015, the Delaware Court of Chancery, acting on remand from the Delaware Supreme Court, issued a letter opinion in the litigation begun by PharmAthene, Inc. in 2006.
Poxvirus Infections and Vestibular Diseases Pipeline Market Drugs and Companies Review H2 2014
PRWeb - Fri Nov 28, 7:30PM CST
The report "Poxvirus Infections Pipeline Review H2 2014" provides comprehensive information on the therapeutic development for Poxvirus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Poxvirus Infections and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.reportsnreports.com/reports/318830...-2014.html .
PharmAthene Announces U.S. Bankruptcy Court Partially Lifts Litigation Stay To Permit Delaware Court To Proceed Towards Final Judgment
PR Newswire - Wed Oct 08, 11:30AM CDT
PharmAthene, Inc. (NYSE MKT: PIP) today announced that the United States Bankruptcy Court for the Southern District of New York has partially lifted the stay of PharmAthene's litigation against SIGA Technologies, Inc., in the Delaware Court of Chancery. The order allows the Chancery Court to issue a final judgment and the parties to pursue appeals thereof. Enforcement of any judgment, once entered will remain subject to the Bankruptcy Court stay.
PIP: 2.49 (unch)
